Effects of a Hydrosoluble Bacterial Extract from Escherichia Coli (OM-89) on Cytokine Production by Peripheral Blood Mononuclear Cells from Healthy Subjects and Patients with Rheumatoid Arthritis

References

• van Pham T, Kreis B, Corradin-Betz S, Bauer J, Mauël J. Metabolic and functional stimulation of lyphocytes and macrophages by an E. coli extract (OM-89): in vitro studies. J Biol Respouse Mod 1990; 9: 231–40
   PubMedGoogle Scholar
• Rosenthal M. Effect of a bacterial extract on cellular and humoral immune responses in humans. J Immunopharmacol 1986; 8: 315–25
   PubMedGoogle Scholar
• Frey C, Obolensky W, Wyss H. Treatment of recurrent urinary tract infections: efficacy of an orally administered biological response modifier. Urol Int 1986; 41: 444–6
   PubMed Web of Science ®Google Scholar
• Keller R, Hinz G. Die Wirkung eines oralen polyvalenten bakterienlysates (Broncho-Vaxom) bei chronischer Bronchitis. Prax Klin Pneumol 1984; 38: 225–8
   PubMedGoogle Scholar
• Rosenthal M, Plattner S. The treatment of rheumatoid arthritis with OM-8930, a bacterial immu-nostimulating agent. Z Rheumatol 1981; 40: 228–31
   PubMed Web of Science ®Google Scholar
• Losa G A, Maestroni G JM. Immunological and clinical effects of a bacterial extract (OM-89) in rheumatoid arthritis. Clin Trials J 1988; 25: 12–20
   Google Scholar
• Bahous I, Rosenthal M. Basic treatment of rheumatoid arthritis with an immunomodulating agent at two distinct dosage regimens: a double blind clinical study. Int J Immunother 1987; 3: 265–70
   Web of Science ®Google Scholar
• Vischer TL. A double blind multicentre study of OM-8980 and auranofin in rheumatoid arthritis. Ann Rheum Dis 1988; 47: 582–7
   PubMed Web of Science ®Google Scholar
• Brackertz D, Vischer TL. OM-8980 in rheumatoid arthritis: a 6-month double-blind placebo controlled multicenter study. J Rheumatol 1989; 16: 19–23
   PubMed Web of Science ®Google Scholar
• Hauzeur J P, Appelboom T. Double-blind, placebo controlled study of OM-8980 in rheumatoid arthritis. Rheumatol Int 1989; 9: 71–6
   PubMed Web of Science ®Google Scholar
• Emery P, Panayi G S, Nouri ME. Interleukin-2 reverses deficient cell-mediated immune response in rheumatoid arthritis. Clin Exp Immunol 1984; 57: 123–8
   PubMed Web of Science ®Google Scholar
• Reuter A, Bernier J, Vrindts-Gevaert Y, et al. Production of interferon-γ by peripheral blood mononuclear cells from normal subjects and from patients with rheumatoid arthritis. Clin Exp Rheumatol 1988; 6: 347–54
   PubMed Web of Science ®Google Scholar
• Miyasaka N, Nakamura T, Russell I J, Talal N. Interleukin-2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 1984; 31: 109–16
   PubMedGoogle Scholar
• Combe B, Pope R M, Fishbach L M, Dennell B, Baron S, Talal N. Interleukin-2 in rheumatoid arthritis: production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. Clin Exp Immunol 1985; 59: 520–31
   PubMed Web of Science ®Google Scholar
• Hasler F, Bluestein H G, Zvaiffer N J, Epstein LB. Analysis of the defect responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished γ-interferon production in response to autologous stimulation. J Exp Med 1983; 157: 173–81
   PubMed Web of Science ®Google Scholar
• Ropes M W, Bennett E A, Cobb S, Jacox R, Jessar R. Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958; 9: 175–6
   PubMedGoogle Scholar
• Franchimont P, Reuter A, Vrindts-Gevaert Y, et al. Production of tumour necrosis factor-a, interferon-γ and interleukin-2 by peripheral blood mononuclear cells of subjects suffering from rheumatoid arthritis. Scand J Rheumatol 1988; 17: 203–12
   PubMed Web of Science ®Google Scholar
• Reuter A, Bernier J, Ph Gysen, . A RIA for tumor necrosis factor (TNF-α) and interleukin-1β (IL-1β) and their direct determination in serum. Monokines and other non-lymphocytic cytokines., M C Powanda, J J Oppenheim, M J Kluger, C A Dinarello, et al. Alan R. Liss, New York 1988; 377–81
   Google Scholar
• Greenwood F, Hunter W, Glover J. The preparation of 131I-labelled human growth hormone of high specific radioactivity. Biochem J 1963; 89: 114–24
   PubMed Web of Science ®Google Scholar
• Franchimont P, Ch Bouffioux, Reuter A, et al. Radioimmunoassay of prostatic acid phosphatase: validation and clinical application. Int J Cancer 1983; 1: 149–55
   Google Scholar
• Bernier J, Reuter A, Vrindts-Gevaert Y, Gathy Meuleman R, Frere M C, Franchimont P. Radioim-munological study of the regulation of interleukin-2 production in peripheral blood mononuclear cell cultures from normal subjects and rheumatoid arthritis patients. Clin Exp Rheumatol 1989; 7: 35–41
   PubMed Web of Science ®Google Scholar
• Zerbe GO. Randomization analysis of the completely randomized design extended to growth and response curves. J Am Stat Analysis 1979; 74: 215–21
   Web of Science ®Google Scholar
• Zar JH. Comparing simple linear regression equations. Biostatistical analysis.2nd Ed., J H Zar. Englewood Cliffs, Prentice-Hall, NJUSA 1984; 292–8
   Google Scholar
• Chattopadhyay C, Chattopadhyay H, Natvig J, Michaelsen T E, Melbye OJ. Lack of suppressor cell activity in rheumatoid synovial lymphocytes. Scand J Immunol 1979; 10: 309–16
   PubMed Web of Science ®Google Scholar
• Keystone E C, Gladman D D, Buchanan R, Cane D, Poplonski L. Impaired antigen-specific suppressor cell activity in patients with rheumatoid arthritis. Arthritis Rheum 1980; 23: 1246–50
   PubMedGoogle Scholar
• Tosato G, Steinberg A D, Blaese RM. Defective EBV specific T-cell function in rheumatoid arthritis. N Engl J Med 1981; 305: 1238–43
   PubMed Web of Science ®Google Scholar
• Sakane T, Takada S, Murakawa F, et al. Analysis of suppressor T cell function in patients with rheumatoid arthritis defects in production of and responsiveness to concanavalin A-induced suppressor cells. J Immunol 1982; 129: 1972–7
   PubMed Web of Science ®Google Scholar
• Youinou P Y, Irving W L, Shipley M, et al. Evidence for B cell activation in patients with active rheumatoid arthritis. Clin Exp Immunol 1984; 55: 91–8
   PubMed Web of Science ®Google Scholar
• Krane S M, Simon LS. Rheumatoid arthritis: clinical features and pathogenetic mechanisms. Med Clin North Am 1986; 70: 263–84
   PubMed Web of Science ®Google Scholar
• Wybran J, Libin M, Schandenne L. Activation of natural killer cells and cytokine production in man by bacterial extracts. Immunopharmacol Immunotoxicol 1989; 11: 17–32
   PubMed Web of Science ®Google Scholar
• Podleski W K, Allman JR. Inhibition of antibody dependent allergic autocytotoxicity (ACT) in rheumatoid arthritis (RA) by OM-89. Allergy Proc 1988; 9: 497
   Google Scholar
• Franchimont P, Bassleer C. New diagnostic tools and methodological approaches: an outlook to the future. Scand J Rheumatol 1989; 80: 29–31, suppl.
   Google Scholar
• Fontana A, Hengartner H, Weber E, Fehr K, Grob P I, Cohen G. Interleukin-1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 1982; 2: 49–53
   PubMed Web of Science ®Google Scholar
• McKeown M J, Hall N D, Corvalan J RF. Defective monocyte accessory function due to surface sulphydryl (SH) oxidation in rheumatoid arthritis. Clin Exp Immunol 1984; 56: 607–13
   PubMed Web of Science ®Google Scholar
• Kornbluth R S, Edington TS. Tumor necrosis factor production by human monocytes is a regulated event: induction of INR-α-mediated cellular cytotoxicity by endoxin. J Immunol 1986; 137: 2585–91
   PubMed Web of Science ®Google Scholar
• Philips R, Epstein LB. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself: γ -interferon and interleukin-1. Nature 1986; 323: 86–9
   PubMed Web of Science ®Google Scholar
• McKenna R M, Ofosu-Appiah W, Warrington R J, Wilkins JA. Interleukin-2 production and responsiveness in active and inactive rheumatoid arthritis. J Rheumatol 1986; 13: 28–33
   PubMed Web of Science ®Google Scholar
• Buchan G, Barrett K, Fujita T, Taniguchi T, Maini R, Feldmann M. Detection of activated T cell products in the rheumatoid joint using cDNA probes to interleukin-2 (IL-2) IL-2 receptor and IFN-γ. Clin Exp Immunol 1988; 71: 295–301
   PubMed Web of Science ®Google Scholar
• Kåss E, Waalen K, Førre O. Rheumatoid synovial cells are activated in vivo. Inhibition of the spontaneous interleukin 2-driven proliferation by anti-Tac and cyclosporin. Clin Exp Rheumatol 1987; 5: 58, suppl. 2
   Google Scholar
• Tsokos G C, Boumpas D R, Smith J Y, Djeu S MY, Balow J E, Rook AH. Deficient y-interferon production in patients with systemic lupus erythematosus. Arthritis Rheum 1986; 29: 1210–5
   PubMedGoogle Scholar
• Wybran J, Libin M, Schandenne L. Enhancement of cytokine production and natural killer activity by an E. coli extract. Onkologie 1989; 12: 23–5
   Google Scholar